1 김지영, "패혈증 환자에서의 혈액응고계의 변화에 대한 고찰" 대한진단검사의학회 27 (27): 157-161, 2007
2 Kienast J, "Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without dissemi-nated intravascular coagulation" 4 (4): 90-97, 2006
3 Iba T, "The usefulness of antithrombin activity monitoring during antithrombin supplementation in patients with sepsis-associated disseminated intravascular coagulation" 135 (135): 897-901, 2015
4 Iba T, "Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation : a perspective from Japan" 103 (103): 253-261, 2016
5 하상욱, "Performance Evaluation of Five Different Disseminated Intravascular Coagulation (DIC) Diagnostic Criteria for Predicting Mortality in Patients with Complicated Sepsis" 대한의학회 31 (31): 1838-1845, 2016
6 Hayakawa M, "Optimal Antithrombin Activity Threshold for Initiating Antithrombin Supplementation in Patients With Sepsis-Induced Disseminated Intravascular Coagulation : A Multicenter Retrospective Observational Study" 24 (24): 874-883, 2018
7 Warren BL, "High-dose antithrombin III in severe sepsis : a randomized controlled trial" 286 (286): 1869-1878, 2001
8 Umemura Y, "Efficacy and safety of anticoagulant therapy in three specific populations with sepsis : a meta-analysis of randomized controlled trials" 14 (14): 518-530, 2016
9 Kushimoto S, "Clinical course and outcome of disseminated intravascular coagulation diagnosed by Japanese Association for Acute Medicine criteria. Comparison between sepsis and trauma" 100 (100): 1099-1105, 2008
10 Yamakawa K, "Benefit profile of anticoagulant therapy in sepsis : a nationwide multicentre registry in Japan" 20 (20): 229-, 2016
1 김지영, "패혈증 환자에서의 혈액응고계의 변화에 대한 고찰" 대한진단검사의학회 27 (27): 157-161, 2007
2 Kienast J, "Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without dissemi-nated intravascular coagulation" 4 (4): 90-97, 2006
3 Iba T, "The usefulness of antithrombin activity monitoring during antithrombin supplementation in patients with sepsis-associated disseminated intravascular coagulation" 135 (135): 897-901, 2015
4 Iba T, "Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation : a perspective from Japan" 103 (103): 253-261, 2016
5 하상욱, "Performance Evaluation of Five Different Disseminated Intravascular Coagulation (DIC) Diagnostic Criteria for Predicting Mortality in Patients with Complicated Sepsis" 대한의학회 31 (31): 1838-1845, 2016
6 Hayakawa M, "Optimal Antithrombin Activity Threshold for Initiating Antithrombin Supplementation in Patients With Sepsis-Induced Disseminated Intravascular Coagulation : A Multicenter Retrospective Observational Study" 24 (24): 874-883, 2018
7 Warren BL, "High-dose antithrombin III in severe sepsis : a randomized controlled trial" 286 (286): 1869-1878, 2001
8 Umemura Y, "Efficacy and safety of anticoagulant therapy in three specific populations with sepsis : a meta-analysis of randomized controlled trials" 14 (14): 518-530, 2016
9 Kushimoto S, "Clinical course and outcome of disseminated intravascular coagulation diagnosed by Japanese Association for Acute Medicine criteria. Comparison between sepsis and trauma" 100 (100): 1099-1105, 2008
10 Yamakawa K, "Benefit profile of anticoagulant therapy in sepsis : a nationwide multicentre registry in Japan" 20 (20): 229-, 2016
11 Tagami T, "Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation : an observational nationwide study" 12 (12): 1470-1479, 2014
12 Iba T, "A Proposal of the Modification of Japanese Society on Thrombosis and Hemostasis(JSTH)Disseminated Intravascular Coagulation(DIC)Diagnostic Criteria for Sepsis-Associated DIC" 24 (24): 439-445, 2018